A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma
Bladder Cancer · 24.04.2022 · 8 (2) · 179-192
DOI: 10.3233/blc-211592 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bladder Cancer, online erschienen am 24.04.2022. Verfasst von Nobuaki Shimizu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Gunma Prefectural Cancer Center, Ota, Gunma, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Effective maintenance therapy for urothelial carcinoma (UC) is needed to delay progression after first-line chemotherapy. OBJECTIVE: To evaluate S-588410, a cancer peptide vaccine containing five human leukocyte antigen (HLA)-A * 24:02-restricted epitope peptides derived from five cancer-testis antigens (DEPDC1, MPHOSPH1, URLC10, CDCA1, and KOC1) in chemotherapy-treated, clinically stable patients with advanced or metastatic UC. MATERIALS AND METHODS: This open-label, international, phase 2 trial enrolled patients with UC who had completed≥4 cycles of first-line platinum-containing chemotherapy without disease progression. Forty-five HLA-A * 24:02-positive patients received subcutaneous injections of S-588410 (Montanide ISA 51 VG with 1 mg/mL of each peptide) weekly for 12 weeks then once every 2 weeks thereafter for up to 24 months. Thirty-six HLA-A * 24:02-negative patients did not receive S-588410 (observation group). The primary endpoint was the rate of cytotoxic T-lymphocyte (CTL) induction against≥1 of the peptides at 12 weeks. RESULTS: The CTL induction rate in the S-588410 group was 93.3% ( p < 0.0001, one-sided binomial test with a rate of≤50% as the null hypothesis). The antitumor response rate was 8.9% in the S-588410 group and 0% in the observation group; median progression-free survival was 18.1 versus 12.5 weeks and median overall survival was 71.0 versus 99.0 weeks, respectively. The most frequent treatment-emergent adverse event was injection-site reactions (47 events, grades 1–3) reported in 93.3% ( n = 42/45) of participants. CONCLUSIONS: S-588410 demonstrated a high CTL induction rate, acceptable safety profile, and modest clinical response, as maintenance therapy in participants with advanced or metastatic UC who had received first-line platinum-based chemotherapy (EudraCT 2013-005274-22).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Gunma Prefectural Cancer Center, Ota, Gunma, Japan.
- The Clatterbridge Cancer Centre, Wirral, UK.
- Department of Urology, Iwate Medical University, Morioka, Iwate, Japan.
- Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Clinical Development, Shionogi & Co., Ltd., Osaka, Japan.
- Biostatistics Center, Shionogi & Co., Ltd., Osaka, Japan.
Zitieren
APA
Shimizu, N., Hussain, S. A., Obara, W., Yamasaki, T., Takashima, S., Hasegawa, T., Iguchi, M., Igarashi, K., Ogawa, O., & Fujioka, T. (2022). A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma. Bladder Cancer, 8(2), 179-192. https://doi.org/10.3233/blc-211592
Vancouver
Shimizu N, Hussain SA, Obara W, Yamasaki T, Takashima S, Hasegawa T, et al. A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma. Bladder Cancer. 2022;8(2):179-192. doi:10.3233/blc-211592
BibTeX
@article{Shimizu2022,
author = {Shimizu, Nobuaki and Hussain, Syed A and Obara, Wataru and Yamasaki, Toshinari and Takashima, Satoru and Hasegawa, Takahiro and Iguchi, Motofumi and Igarashi, Kenji and Ogawa, Osamu and Fujioka, Tomoaki},
title = {A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma},
journal = {Bladder Cancer},
year = {2022},
volume = {8},
number = {2},
pages = {179--192},
doi = {10.3233/blc-211592}
}
EUVIMED